Search alternatives:
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significantly increased » significant increase (Expand Search)
increased decrease » increased release (Expand Search), increased crash (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
501
Data for Fig 6D.
Published 2024“…In <i>vivo</i> experiments further showed that PRV UL4 (<sup>132</sup>DVAADAAAEAAAAE<sup>145</sup>) mutated strain (PRV-UL4<sup>mut</sup>) infection did not lead to a significant decrease in viral titers at 12 h. p. i, but it induced lower levels of IL-1β, IL-18, and GSDMD-NT, which led to an alleviated inflammatory infiltration and pathological damage in the lungs and brains, and a lower death rate compared with wild-type PRV strain infection. …”
-
502
Data for Fig 5D.
Published 2024“…In <i>vivo</i> experiments further showed that PRV UL4 (<sup>132</sup>DVAADAAAEAAAAE<sup>145</sup>) mutated strain (PRV-UL4<sup>mut</sup>) infection did not lead to a significant decrease in viral titers at 12 h. p. i, but it induced lower levels of IL-1β, IL-18, and GSDMD-NT, which led to an alleviated inflammatory infiltration and pathological damage in the lungs and brains, and a lower death rate compared with wild-type PRV strain infection. …”
-
503
Data for Figs 8A–8H, 9A–9K, 10A–10I.
Published 2024“…In <i>vivo</i> experiments further showed that PRV UL4 (<sup>132</sup>DVAADAAAEAAAAE<sup>145</sup>) mutated strain (PRV-UL4<sup>mut</sup>) infection did not lead to a significant decrease in viral titers at 12 h. p. i, but it induced lower levels of IL-1β, IL-18, and GSDMD-NT, which led to an alleviated inflammatory infiltration and pathological damage in the lungs and brains, and a lower death rate compared with wild-type PRV strain infection. …”
-
504
-
505
-
506
-
507
Patient enrollment and inclusion information.
Published 2025“…During chemotherapy, PVS decreased significantly from 3M to 12M. Subsequently, from 12M to FollowUp, PVS increased again. …”
-
508
Normalized significant family changes in abundance.
Published 2025“…<p>A) <i>Erysipelotrichaceae</i> significantly increased with CCE treatment; B) <i>Bacteroidales_unclassified</i> significantly decreased with CCE treatment; C) <i>Desulfovibrionaceae</i> significantly decreased with CCE treatment; D) <i>Rikenellaceae</i> significantly decreased with CCE treatment; E) <i>Coriobacteriaceae</i> significantly decreased with CCE treatment; F) <i>Erysipelotrichaceae</i> significantly increased with TRE treatment.…”
-
509
Downregulation of <i>TcPiezo1</i> expression decreases Ca<sup>2+</sup> entry in <i>T. cruzi.</i>
Published 2025“…(B) Downregulation of <i>TcPiezo1</i> expression showed a significant decrease of intracellular Ca<sup>2+</sup> (+Tet). …”
-
510
-
511
Projected global leukemia burden, 1990-2050.
Published 2025“…Conclusion: Although there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. …”
-
512
Correlation between HDI and EAPC.
Published 2025“…Conclusion: Although there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. …”
-
513
Global leukemia incidence and EAPC, 1990-2021.
Published 2025“…Conclusion: Although there has been a marked decrease in global leukemia incidence, mortality, and DALYs over the past 31 years, the rise in new cases due to population growth suggests an increasing overall disease burden by 2050. …”
-
514
-
515
-
516
-
517
-
518
Activity of xylanase in mixed feed and liver (mg saccharide/g sample/h), n = 12/treatment.
Published 2024Subjects: -
519
-
520